The results of the CSL Behring-sponsored Phase III COMPACT (clinical study for optimal management of preventing angioedema with low volume subcutaneous C1-inhibitor replacement therapy) trial showed that twice-weekly, self-administered subcutaneous injections of CSL830 were associated with a significant reduction in the frequency of acute HAI attacks, compared with placebo, with only mild and transient adverse effects.
“More than 50% of patients had no moderate-to-severe attacks while they were receiving CSL830,” noted UK clinical researcher Hilary Longhurst...